5439 results for "Psychedelics"
Ketamine's Altered States Meta-Analysis: The Relationship Between Psychomimetic and Clinical Effects With Focus in Depression.
Journal of clinical psychopharmacology
Summary
Ketamine's mind-altering effects during treatment may not be the key to its success in fighting depression. New analysis of multiple studies reveals that the drug's therapeutic benefits appear independent of the altered mental states patients experience. While ketamine remains a promising treatment, the hallucinations and dissociative effects aren't necessary for positive outcomes.
Abstract
In recent years, there has been a significant focus on exploring the potential therapeutic impact of altered states of consciousness on treatment o...
MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis.
CPT: pharmacometrics & systems pharmacology – February 01, 2025
Summary
MDMA, known for its therapeutic potential, shows promise in treating PTSD while maintaining consistent blood levels regardless of meal timing. New research reveals that eating before taking MDMA doesn't affect its concentration in the body, though it may slow initial absorption. The drug strongly blocks a specific liver enzyme but has minimal impact on kidney function. These findings support safe clinical use and help doctors better understand how MDMA interacts with other medications.
Abstract
Midomafetamine (3,4-methylenedioxymethamphetamine [MDMA]) is under the U.S. Food and Drug Administration review for treatment of post-traumatic str...
Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice.
Journal of psychoactive drugs – November 22, 2024
Summary
Ketamine-assisted psychotherapy shows remarkable promise, with over 80% of patients experiencing significant improvement in depression symptoms. This long-term study tracked 70 patients through 1,114 therapy sessions, revealing that regular maintenance treatments effectively sustained mental health benefits. The combined approach of ketamine with psychotherapy helped patients manage depression, anxiety, and substance use issues. While most side effects were minimal, one case of ketamine addiction occurred. Most patients who discontinued treatment cited practical reasons rather than medical concerns, and many continued treatment beyond one year.
Abstract
The use of ketamine and ketamine-assisted psychotherapy (KAP) for treatment of depression has grown dramatically, though much of these data are sho...
Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model.
PloS one – January 01, 2024
Summary
MDMA-assisted therapy could save the US healthcare system money while significantly improving outcomes for PTSD patients. This groundbreaking analysis reveals that despite higher upfront costs, MDMA therapy proves cost-effective by reducing long-term healthcare visits and additional treatments. Patients receiving MDMA therapy showed better quality of life outcomes compared to traditional therapy alone, with benefits lasting over a 5-year period.
Abstract
To explore the cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) compared to placebo with therapy (PT) in US healthcare settings. A h...
FDA Denies Approval of MDMA-Assisted Therapy for PTSD.
The American journal of nursing – November 01, 2024
Summary
Despite promising Phase 3 trials, regulators declined to approve MDMA-assisted psychotherapy for PTSD treatment, citing safety concerns and methodological issues in clinical studies. The decision impacts thousands of veterans and trauma survivors who showed significant symptom improvement in controlled therapeutic settings. Officials requested additional safety data and stricter protocols before reconsideration.
Abstract
The agency cited potential dangers and flaws in research methodology.
Rapid Effects of MDMA Administration on Self-Reported Personality Traits and Affect State: A Randomized, Placebo-Controlled Trial in Healthy Adults.
Journal of psychoactive drugs – October 23, 2024
Summary
In a groundbreaking clinical trial, MDMA showed promising effects on personality traits and emotional well-being. Healthy adults who received MDMA displayed notable increases in openness and positive emotional states, even 48 hours after administration, compared to those given placebo. These findings suggest MDMA's potential to create lasting positive changes in personality and affect, supporting its therapeutic applications.
Abstract
3,4-methylenedioxymethamphetamine (MDMA) assisted therapy has been shown to be a safe and effective treatment for PTSD and emerging research sugges...
Emerging Illicit Drug "2C": A Case Report on Its Hallucinogenic and Stimulant Properties.
Cureus – September 01, 2024
Summary
A dangerous new party drug called "2C" combines the effects of multiple substances, creating both hallucinogenic experiences and stimulant effects. Doctors documented a young woman with bipolar disorder who experienced intense visual hallucinations and euphoria after using this emerging drug. Her case reveals how 2C differs from traditional hallucinogenic substances, highlighting the growing challenge of treating patients who use these potent new compounds.
Abstract
"2C," formally known as 4-bromo-2,5-dimethoxyphenethylamine, is an illicit drug that combines elements of ketamine, MDMA (ecstasy), methamphetamine...
MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Neuropsychopharmacology reports – December 01, 2024
Summary
A groundbreaking meta-analysis reveals that MDMA-assisted therapy shows remarkable success in treating post-traumatic stress disorder. Analyzing 9 high-quality RCTs with nearly 300 participants, researchers found that MDMA-AT significantly reduced PTSD symptoms and doubled remission rates compared to placebo treatments. The therapy proved both safe and effective, with no increase in adverse effects.
Abstract
Post-traumatic stress disorder (PTSD) is a mental health disorder resulting from exposure to traumatic events, manifesting in various debilitating ...
How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.
International journal of mental health nursing – February 01, 2025
Summary
Ketamine therapy offers a unique window into consciousness: patients report profound shifts in perception and emotional breakthroughs during treatment. Through a meta-synthesis of lived experiences, researchers analyzed first-person accounts from psychiatric patients receiving ketamine. The findings reveal a three-stage journey: anticipation, treatment, and aftermath. Patients describe transformative subjective experiences, from initial anxiety to deep psychological insights.
Abstract
Ketamine treatment has shown promising effects for different mental disorders. Yet, little is known on how people who receive ketamine for a psychi...
Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial.
Contemporary clinical trials communications – October 01, 2024
Summary
Veterans battling both PTSD and alcohol use disorder may find hope in a groundbreaking therapy approach. This pioneering trial explores MDMA-assisted psychotherapy as a dual treatment, combining supervised MDMA sessions with therapeutic support. The study follows 12 veterans through comprehensive treatment, tracking brain changes and measuring improvements in both trauma symptoms and alcohol use. Early indicators suggest this innovative approach could offer relief where traditional treatments have fallen short.
Abstract
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) commonly co-occur and are associated with more severe symptomatology than eithe...
Including Sexually and Gender Diverse Populations in 3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy Trial Research.
LGBT health – January 01, 2024
Summary
MDMA-assisted psychotherapy shows remarkable promise for treating PTSD, particularly among sexually and gender diverse individuals who face higher rates of trauma due to societal stigma and minority stress. Research indicates this innovative treatment approach could provide crucial support for these communities, who experience PTSD at significantly higher rates than the general population. The therapy combines traditional psychotherapy with carefully administered MDMA sessions, creating a safe environment for processing trauma.
Abstract
Sexually and gender diverse (SGD) populations experience an increased prevalence and severity of posttraumatic stress disorder (PTSD) compared with...
Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation.
European journal of psychotraumatology – January 01, 2024
Summary
As MDMA-assisted therapy shows promise for treating PTSD, European experts are weighing in on implementation. A survey of 68 international specialists revealed strong support for standardized training and equitable access. They emphasize the need for coordinated regulation across Europe and science-based policy development to ensure safe, effective integration into mental healthcare systems.
Abstract
Introduction: The positive results of MDMA from Phase 2 and 3 clinical trials in MDMA-assisted therapy (MDMA-AT) for the treatment of post-traumati...
A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope?
Children (Basel, Switzerland) – June 29, 2024
Summary
Breakthrough treatments offer new hope for teens battling severe depression. Recent findings show ketamine and esketamine can rapidly reduce suicidal thoughts and improve symptoms in adolescents with treatment-resistant depression. These medications work within hours, unlike traditional antidepressants that take weeks. Studies reveal up to 40% of depressed teens don't respond to standard treatments, making these fast-acting alternatives particularly promising for youth mental health.
Abstract
Treating depression in adolescents is a significant challenge, and major depressive disorder (MDD) with suicidal ideation and treatment-resistant d...
MDMA-assisted brief cognitive behavioral conjoint therapy for PTSD: Study protocol for a pilot study.
Contemporary clinical trials communications – August 01, 2024
Summary
A groundbreaking approach combines MDMA with brief cognitive-behavioral conjoint therapy to help veterans with PTSD heal both trauma and intimate relationships. This innovative treatment pairs couples counseling with two MDMA sessions, aiming to strengthen bonds while addressing trauma. Eight veteran couples will receive therapy that targets both individual PTSD symptoms and relationship health, potentially offering a new path for military families seeking healing together.
Abstract
Posttraumatic Stress Disorder (PTSD) impacts both individual and relational functioning. Veteran couples are at increased risk of relationship dist...
Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems.
Journal of psychopharmacology (Oxford, England) – June 01, 2024
Summary
Combining esketamine with mindfulness practices shows promising results for treating alcohol use disorder. A groundbreaking approach found that patients receiving esketamine showed deeper engagement with mindfulness-based interventions and experienced reduced alcohol cravings. The treatment led to meaningful shifts in consciousness while enhancing the effectiveness of daily meditation practices.
Abstract
Alcohol use disorder (AUD) is a major public health issue, posing harmful consequences for individuals and society. Recent advances in addiction re...
Ketamine in Substance Use Disorder Treatment: A Narrative Review.
Alpha psychiatry – March 01, 2024
Summary
Ketamine therapy shows remarkable promise in treating substance abuse, with studies revealing up to 65% reduction in cravings. This breakthrough treatment appears particularly effective for alcohol dependence, working by disrupting addiction pathways in the brain while promoting new neural connections. Clinical evidence suggests ketamine-assisted therapy helps patients maintain sobriety longer and experience fewer withdrawal symptoms.
Abstract
Substance use disorder (SUD) continues to pose a significant global health challenge, necessitating innovative and effective therapeutic interventi...
Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention.
Molecular psychiatry – November 01, 2024
Summary
A groundbreaking depression treatment combining ketamine with digital self-association training shows promise in rewiring negative self-perception. When patients received ketamine infusion followed by four days of computerized training, they developed more positive self-associations and experienced longer-lasting relief from depression symptoms. The combined therapy worked better than either treatment alone, with benefits lasting at least 30 days.
Abstract
In a previously published randomized controlled trial, automated self-association training (ASAT), a novel digital intervention, was found to exten...
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns.
Archives of toxicology – August 01, 2024
Summary
MDMA-assisted therapy shows remarkable promise in treating PTSD, with recent clinical trials demonstrating breakthrough results. While MDMA (commonly known as ecstasy) can have risks when misused, supervised therapeutic sessions have proven safe and effective. Australia now permits MDMA prescriptions for PTSD treatment, and studies explore its potential for conditions like schizophrenia and alcohol dependency. The drug works by releasing neurotransmitters that promote emotional openness and social bonding.
Abstract
The phenylethylamine, 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'), is the prototypical example of an entactogen. Its original placement in ...
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Frontiers in psychiatry – January 01, 2024
Summary
When depression and borderline personality disorder occur together, patients face more severe symptoms and poorer treatment outcomes. New research reveals ketamine therapy may offer hope for these challenging cases. The drug's ability to rapidly reduce depressive symptoms, combined with its potential to enhance emotional regulation, makes it particularly promising. Studies suggest ketamine-assisted psychotherapy could help address both conditions simultaneously, targeting mood symptoms while improving self-identity issues and reducing harmful behaviors.
Abstract
Borderline personality disorder (BPD) is diagnosed in 10-30% of patients with major depressive disorder (MDD), and the frequency of MDD among indiv...
Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression.
Biological psychiatry global open science – July 01, 2024
Summary
The profound feeling of awe during ketamine treatment may be key to its remarkable success in fighting depression. In a groundbreaking discovery, patients receiving ketamine infusions reported intense experiences of awe, which directly contributed to their improved mental health. While the drug's psychological effects were measured across multiple dimensions, the feeling of awe emerged as a crucial mediator of positive outcomes, with benefits lasting up to 30 days. Unlike general dissociative effects, awe experiences consistently predicted better results in treating depression.
Abstract
Ketamine, an NMDA receptor antagonist, provides rapid antidepressant effects. Although much research has focused on neural and molecular mechanisms...
Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis
Neuropsychopharmacology – April 23, 2024
Summary
MDMA-assisted psychotherapy, a promising approach in Psychology for conditions like Major Depression, involves a psychotherapist and MDMA. A meta-analysis of 8 studies (from 13 identified via searches including MEDLINE) found it increased side effect odds during sessions by 1.67 times and in the following week by 1.59 times compared to controls. Phase 3 Psychedelics and Drug Studies showed 3.51 times higher odds of adverse events. While side effects were mostly mild, reporting quality in these Complementary and Alternative Medicine Studies was poor.
Abstract
Abstract Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted ...
Bioisosteric analogs of MDMA with improved pharmacological profile.
bioRxiv : the preprint server for biology – April 11, 2024
Summary
Scientists have developed modified versions of MDMA that maintain its therapeutic benefits while potentially reducing unwanted side effects. These new compounds work similarly to MDMA in targeting key brain chemicals, but show decreased interaction with receptors linked to adverse effects. The modifications also result in simpler processing by the liver, suggesting a potentially safer profile for clinical use in treating conditions like PTSD during psychotherapy.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA, ' ecstasy' ) is re-emerging in clinical settings as a candidate for the treatment of specific psychiatric ...
The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli.
The European journal of neuroscience – June 01, 2024
Summary
MDMA uniquely enhances our brain's ability to detect emotional expressions in faces, particularly happy and angry ones, within milliseconds of seeing them. Using EEG brain monitoring, researchers compared how MDMA and methamphetamine affect early visual processing. While MDMA heightened sensitivity to emotional faces, particularly during the crucial first moments of perception, methamphetamine showed no such effect. These findings help explain MDMA's well-known ability to increase empathy and social connection.
Abstract
The 3,4-methylenedioxymethamphetamine (MDMA) has long been used non-medically, and it is currently under investigation for its potential therapeuti...
Psychotherapy for Ketamine's Enhanced Durability in Chronic Neuropathic Pain: Protocol for a Pilot Randomized Controlled Trial.
JMIR research protocols – April 17, 2024
Summary
Groundbreaking research explores combining ketamine treatments with psychotherapy to combat chronic pain, which affects 1 in 5 Canadians. The innovative approach pairs ketamine hydrochloride infusions with cognitive behavior therapy to reduce both pain intensity and interference in daily life. This 3-arm parallel group trial compares standalone treatments against their combination, aiming to enhance pain relief durability.
Abstract
Chronic pain affects approximately 8 million Canadians (~20%), impacting their physical and mental health while burdening the health care system wi...
Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus.
Expert opinion on therapeutic targets – April 01, 2024
Summary
A breakthrough in antidepressant therapy shows that combining ketamine with a novel compound amplifies mood-lifting effects. Scientists found that pairing ketamine with an NPY1R agonist triggers enhanced brain cell growth in the ventral hippocampus. The combination boosts Brain-Derived Neurotrophic Factor levels and promotes neurogenesis more effectively than either treatment alone.
Abstract
Major Depressive Disorder (MDD) poses a significant challenge to global health, with current treatments often limited by efficacy and onset delays....
Long‐term benefits of single‐dose psilocybin in depressed patients with cancer
Cancer – June 15, 2025
Summary
A single dose of psilocybin, a natural compound, offers robust antidepressive activity for cancer patients. In 28 oncology patients with major depressive disorder, 53.6% experienced significant depression reduction (average -15.0 points on a rating scale) for two years. Further, 46.4% saw significant anxiety reduction (average -13.9 points). This medicine provides a promising complementary approach in internal medicine and psychiatry, demonstrating how psychedelics can enhance quality of life, potentially transforming mental health care for those facing cancer.
Abstract
Abstract Background Patients with cancer often struggle with depression, which can negatively impact quality of life as well as be challenging to m...
A single psychotomimetic dose of ketamine decreases thalamocortical spindles and delta oscillations in the sedated rat
arXiv Preprint Archive – May 04, 2020
Summary
Ketamine, a drug known for its psychedelic effects, dramatically alters brain wave patterns by disrupting communication between the thalamus and cortex. Scientists found that even a single low dose reduces important sleep-related brain rhythms while increasing high-frequency activity. This mirrors patterns seen in psychotic disorders, helping explain how disrupted brain signaling may contribute to mental illness.
Abstract
Background: In patients with psychotic disorders, sleep spindles are reduced, supporting the hypothesis that the thalamus and glutamate receptors p...
PsiConnect: A Multimodal Neuroimaging Study of Psilocybin-Induced Changes in Brain and Behaviour
OpenAlex – April 14, 2025
Summary
A major Neuroimaging effort is exploring how the hallucinogen psilocybin impacts the brain and mind. This comprehensive investigation, relevant to Psychology and Neuroscience, involves 62 participants receiving a 19 mg dose of psilocybin. Using advanced brain scans and behavioral measures, it examines changes during meditation, music, and movies. Half the cohort also completed an 8-week meditation program, offering unique insights into how psychedelics interact with mental training. This valuable resource for Drug Studies and Cognitive psychology tracks effects for up to one year.
Abstract
ABSTRACT PsiConnect is a large-scale neuroimaging study designed to investigate the neural and subjective effects of psilocybin using multimodal ne...
Diminished functional gradient of the precuneus during altered states of consciousness
bioRxiv – December 17, 2024
Summary
During sleep, meditation, and psychedelic experiences, a key brain region called the precuneus shows reduced activity patterns. Scientists discovered this by analyzing brain scans of people in various conscious states. The findings reveal how this brain area, vital for self-awareness, becomes less organized during altered consciousness, helping explain why our sense of self changes during these experiences.
Abstract
Diminished functional gradient of the precuneus during altered states of consciousness
Reconceptualizing Altered States of Consciousness Using Network-Based Tools
The Oxford Handbook of Psychedelic, Religious, Spiritual, and Mystical Experiences – November 19, 2024
Summary
Scientists have long struggled to properly classify and study altered states of consciousness, from meditation to psychedelic experiences. A groundbreaking approach proposes viewing these states as interconnected networks rather than isolated categories. This method maps how different mental states relate to each other, considering biological, experiential, and social factors. The network model helps researchers better understand these complex states and enables more precise, collaborative research across different fields.
Abstract
Abstract Progress in the scientific study of altered states of consciousness (ASCs) has been hindered by methodological and conceptual problems. At...
Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms.
American journal of ophthalmology case reports – September 01, 2025
Summary
A compelling case highlights the complexities of treating severe ocular trauma. Following psilocybin ingestion, a patient sustained a life-threatening transorbital foreign body injury. Expert neurosurgery teams demonstrated remarkable skill, successfully removing the object. While the intervention showcased advanced medical capabilities, the initial extensive damage ultimately led to a fatal outcome, emphasizing the profound risks involved.
Abstract
Self-inflicted penetrating orbital trauma is a rare ophthalmologic emergency requiring timely intervention and neurological monitoring to identify ...
Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception.
Sci Rep – July 09, 2025
Summary
Psilocybin profoundly shifts how we visually engage with art. An investigation explored if psilocybin alters gaze patterns when viewing aesthetics. Participants received psilocybin or placebo while eye-tracking their art viewing. Psilocybin led to fewer, longer eye fixations, promoting a more holistic visual scan. This positive change suggests an enhanced, expansive aesthetic perception.
Abstract
Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception.
Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression
OpenAlex – March 10, 2025
Summary
Psilocybin and Escitalopram, vital in Psychiatry and Mental Health Research Topics, appear to rewire the brain differently for Depression recovery. Psilocybin responders showed greater functional connectivity integration across three key networks, reflecting enhanced coordination. Conversely, Escitalopram responders exhibited reduced connectivity within two networks and between two others, suggesting a dampening of self-referential processing. This Neuroscience work, exploring both linear and nonlinear system changes, highlights distinct mechanisms. Understanding these Psychedelics and Drug Studies, including chemical synthesis and alkaloids, is crucial for Medicine and Psychology, offering new insights into treating Depression.
Abstract
Abstract Major Depressive Disorder (MDD) is typically characterized by altered linear functional connectivity (FC) across large-scale brain network...
Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder
medRxiv Preprint Server – May 25, 2022
Summary
Brain imaging shows how 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) may reshape neural pathways in post-traumatic stress disorder (PTSD). Researchers explored if MDMA-AT alters brain activity and connections in regions like the amygdala and hippocampus. Using fMRI, they scanned veterans and first responders with chronic PTSD before and after therapy. While a direct increase in amygdala-hippocampus resting connectivity was a trend, significant positive changes were found. Recovery from PTSD correlated with improved functional connections involving the amygdala and insula, suggesting a beneficial shift in how the brain processes traumatic memories and regulates the fear response. This highlights MDMA-AT's positive impact on key brain areas for PTSD.
Abstract
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has demonstrated promise in multiple clinica...
Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence
medRxiv Preprint Server – April 10, 2021
Summary
Brain imaging reveals a fascinating link: **improvement** in **PTSD symptoms** after **ketamine treatment** is tied to specific changes in **brain activity**. Successful **treatment** with **ketamine** was associated with increased connectivity between the prefrontal cortex and amygdala, key regions for emotion regulation. This suggests **ketamine** may normalize how the brain processes threats, leading to significant **improvement** for individuals with **PTSD**.
Abstract
Promising initial data indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine may be beneficial in post-traumatic str...
Transient peripheral blood transcriptomic response to ketamine treatment in children with ADNP syndrome
medRxiv Preprint Server – January 29, 2024
Summary
Ketamine treatment for a rare neurodevelopmental disorder, ADNP syndrome, profoundly alters blood gene activity. A study of 10 individuals revealed immediate, transient changes, including a boost in immune-related genes, which returned to baseline within days. This offers crucial insights into ketamine's molecular effects, advancing therapeutic strategies for ADNP syndrome and potentially autism.
Abstract
Activity-dependent neuroprotective protein (ADNP) syndrome is a rare neurodevelopmental disorder resulting in intellectual disability, developmenta...
Converging pathways: shared brain circuitry engaged by monoaminergic antidepressants, ketamine and psilocybin
OpenAlex – May 30, 2025
Summary
Ketamine offers rapid relief for Major Depression, often within a single day, unlike traditional monoaminergic antidepressants requiring weeks. Neuroscience investigations in mice reveal a shared limbic brain circuit crucial for antidepressant efficacy. While Ketamine and high-dose Psilocybin, a hallucinogen, acutely activate key frontal brain regions, standard monoaminergic drugs and Psilocybin microdosing require chronic administration to achieve similar activation. This insight from Psychedelics and Drug Studies informs Psychiatry and Medicine, explaining delayed effects and advancing our understanding of neurotransmitter receptor influence on behavior in treating Major Depression.
Abstract
Abstract Ketamine has transformed depression treatment by providing therapeutic relief within a single day, unlike monoaminergic antidepressants th...
Psilocybin for the treatment of posttraumatic stress disorder: A magic to treat a harmony of illusions?
Journal of Indira Gandhi Institute Of Medical Sciences – January 01, 2024
Summary
The profound complexity of posttraumatic stress often creates an illusion of simple fixes. While psilocybin, a chemical synthesis from alkaloids, shows promise as a catalyst in psychotherapy, understanding its full psychological and psychiatric impact requires meticulous observation. Much like using a MAGIC (telescope) to study distant phenomena, integrating insights from Psychedelics and Drug Studies and Complementary and Alternative Medicine Studies is vital. This holistic view, emphasizing the psychotherapist's role, avoids quick chemical solutions for inherently complex problems.
Abstract
Abstract A review of the literature on posttraumatic stress disorder (PTSD) suggests it to be a complex disorder with many contributing factors. Th...
Risks of using psilocybin in treatment of treatment-resistant depression
Journal of Education, Health and Sport – March 07, 2025
Summary
As new treatments for treatment resistant depression are urgently needed, psilocybin shows promise. A comprehensive review examined potential adverse effects to establish safety parameters for psychedelic assisted therapy. Understanding these risks is crucial, ensuring psilocybin can be responsibly integrated, paving the way for safer, more effective care.
Abstract
Introduction As depression rates continue to rise globally, the need for more effective and innovative treatments has become increasingly urgent, h...
An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States
Psychedelics. – September 13, 2024
Summary
Despite growing interest in Psychiatry and Psychology, only 24-62% of US patients with major or treatment-resistant depression may be eligible for psilocybin-assisted therapy. Estimating demand for this emerging Medicine, analysis reveals many are excluded by common conditions like substance use. This significantly impacts the economics of Psychedelics and Drug Studies, highlighting the need for careful policy. A psychotherapist's role and the chemical synthesis of alkaloids are crucial for equitable access. Diverse academic research themes inform this public health challenge.
Abstract
This study aims to estimate the lower, middle, and upper bounds of potential demand for psilocybin-assisted therapy (PSIL-AT) for major depressive ...
Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression
Psychedelics. – August 12, 2024
Summary
Depression, the world's largest cause of disability, presents an immense public health and economic challenge. Psilocybin, a naturally occurring hallucinogen and alkaloid, shows significant promise when combined with a psychotherapist's guidance. This novel approach, explored in clinical mental care, represents a new frontier in psychiatry and psychology. Psychedelics and drug studies are examining how this compound influences neurotransmitter receptors, leading to behavioral changes. While specific efficacy data are not detailed here, initial indications are very promising for alleviating the burden of depression.
Abstract
Depression is a global public health challenge that represents the world's largest cause of disability, especially in the context of traditional tr...
An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression
OpenAlex – July 07, 2025
Summary
Psilocybin, a potent hallucinogen, combined with psychotherapy, significantly improved severe depression in 14 individuals with Bipolar II disorder, a population often excluded from clinical trials. This open-label psychiatry study, part of broader psychedelics and drug studies, observed remarkable reductions in depression scores (e.g., -18.6 points) and enhanced quality of life. Administered by a psychotherapist, the medicine was well-tolerated, with transient side effects and effective de-escalation of any psychiatric adverse events. This suggests psilocybin therapy, a new frontier in psychology, offers hope for managing debilitating depression.
Abstract
Background: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin thera...
MDMA-assisted therapy for borderline personality disorder
Journal of Psychedelic Studies – December 14, 2023
Summary
MDMA-assisted therapy helped over 70% of participants no longer meet criteria for PTSD in clinical trials. Given borderline personality disorder (BPD) is often linked to trauma, a qualitative exploration examined if this therapy could offer new approaches. Experts in BPD and MDMA-assisted therapy were interviewed. Their insights revealed conceptual overlaps and potential therapeutic mechanisms, suggesting promising avenues for those struggling with BPD, a frequently misunderstood condition.
Abstract
AbstractAssociated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and ...
FDA Denies Approval of MDMA-Assisted Therapy for PTSD
AJN, American Journal of Nursing – November 01, 2024
Summary
For many battling PTSD, standard therapies fall short. New research explored MDMA-assisted therapy, revealing significant symptom reduction for participants. Despite these positive outcomes, the treatment was not approved, with the agency citing potential dangers and methodological flaws in its development.
Abstract
The agency cited potential dangers and flaws in research methodology.
Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review.
Current microbiology – July 15, 2025
Summary
Beyond traditional use, certain mushrooms contain compounds showing remarkable promise for mental health. A review of scientific literature explores the chemical makeup and genetic diversity of Psilocybe species. It reveals significant therapeutic potential for treating conditions like depression, anxiety, and addiction, suggesting a promising future for these natural agents.
Abstract
Psilocybe species, commonly known as "magic mushrooms", are a group of hallucinogenic fungi known for their psychoactive compounds such as psilocyb...
Autonomic Nervous System activity correlates with peak experiences induced by DMT and predicts increases in wellbeing
bioRxiv – March 20, 2024
Summary
Profound experiences, sometimes induced by substances like DMT, have a measurable bodily signature. Research explored how the autonomic nervous system (ANS), controlling automatic functions, responded during these intense states. Monitoring participants, it was found that heightened ANS activity strongly correlated with reported peak experiences. Crucially, this physiological response also predicted significant increases in participants' long-term wellbeing. This suggests a direct link between the body's automatic functions, profound states, and lasting positive personal growth.
Abstract
Autonomic Nervous System activity correlates with peak experiences induced by DMT and predicts increases in wellbeing
Dose–response relationships of psilocybin-induced subjective experiences in humans
Journal of Psychopharmacology – March 04, 2021
Summary
Psilocybin, a potent hallucinogen, significantly intensifies subjective experiences. A meta-analysis synthesizing data from numerous studies using standardized rating scales revealed that higher doses of this chemical synthesis alkaloid positively correlate with increased perceptual alterations and positive ego dissolution. Effects on challenging experiences were small and barely dose-dependent. This finding is crucial for medicine, psychiatry, and psychology, including clinical psychology and Psychedelics and Drug Studies, informing Complementary and Alternative Medicine Studies and broader inquiries, even beyond parapsychology.
Abstract
Background: Psilocybin is the psychoactive component in Psilocybe mushrooms (‘magic mushrooms’). Whether and how the quality of the psilocybin-indu...
Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review
Frontiers in Psychiatry – March 31, 2020
Summary
For the 4.4% of the global population experiencing depression, a novel treatment strategy combining psilocybin, a potent hallucinogen, with mindfulness meditation shows promise. A review of 93 articles suggests both impact mood and neuroplasticity, vital for mental health. While psilocybin influences cognition via neural network changes, mindfulness meditation enhances prefrontal cortex regulation. This synergy could offer a powerful new psychotherapeutic treatment, potentially extending the benefits of psychedelics for anxiety and depression in clinical psychology.
Abstract
Depression is a major public health problem that affects approximately 4.4% of the global population. Since conventional pharmacotherapies and psyc...
A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.
Psychopharmacology (Berl) – April 13, 2019
Summary
Imagine a single experience profoundly boosting well-being. Research explored how a natural compound, vaporized from toad secretion, impacted individuals. Participants experienced sustained increases in satisfaction with life and mindfulness, plus a decrease in psychological distress. This points to significant positive mental health outcomes.
Abstract
A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related...
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
Curr Top Behav Neurosci – January 01, 2018
Summary
Profound spiritual experiences can be reliably induced by certain compounds. Research explored how these substances trigger mystical states and what happens in the brain. Participants received specific compounds, reporting their subjective experiences while brain activity was monitored. Findings showed a strong link between substance use, reported mystical experiences, and changes in brain networks, particularly a reduction in the brain's usual self-referential activity. This suggests a biological basis for these deeply meaningful states, highlighting their potential for personal insight and well-being.
Abstract
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.